These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22886568)

  • 1. Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts.
    Esposito V; Verdina A; Manente L; Spugnini EP; Viglietti R; Parrella R; Pagliano P; Parrella G; Galati R; De Luca A; Baldi A; Montesarchio V; Chirianni A
    J Cell Physiol; 2013 Mar; 228(3):640-5. PubMed ID: 22886568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma.
    Esposito V; Palescandolo E; Spugnini EP; Montesarchio V; De Luca A; Cardillo I; Cortese G; Baldi A; Chirianni A
    Clin Cancer Res; 2006 Apr; 12(8):2634-9. PubMed ID: 16638877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
    Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
    Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism.
    Chung TW; Moon SK; Chang YC; Ko JH; Lee YC; Cho G; Kim SH; Kim JG; Kim CH
    FASEB J; 2004 Nov; 18(14):1670-81. PubMed ID: 15522912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma.
    Chen G; Wang Y; Zhou M; Shi H; Yu Z; Zhu Y; Yu F
    Oncol Rep; 2010 Feb; 23(2):563-70. PubMed ID: 20043122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
    Cui W; Yu CH; Hu KQ
    Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic tumor suppression by adenovirus-mediated inhibitor of growth 4 and interleukin-24 gene cotransfer in hepatocarcinoma cells.
    Xie Y; Lv H; Sheng W; Miao J; Xiang J; Yang J
    Cancer Biother Radiopharm; 2011 Dec; 26(6):681-95. PubMed ID: 21988227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
    Jung KH; Zheng HM; Jeong Y; Choi MJ; Lee H; Hong SW; Lee HS; Son MK; Lee S; Hong S; Hong SS
    Cancer Lett; 2013 Jan; 328(1):176-87. PubMed ID: 22902995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in vivo.
    Hossain MA; Kim DH; Jang JY; Kang YJ; Yoon JH; Moon JO; Chung HY; Kim GY; Choi YH; Copple BL; Kim ND
    Int J Oncol; 2012 May; 40(5):1636-42. PubMed ID: 22322725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.
    Gupta AK; Cerniglia GJ; Mick R; McKenna WG; Muschel RJ
    Cancer Res; 2005 Sep; 65(18):8256-65. PubMed ID: 16166302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and In vitro effect of a nutrient mixture on human hepatocarcinoma cell line SK-HEP-1.
    Roomi MW; Roomi NW; Kalinovsky T; Niedzwiecki A; Rath M
    Exp Oncol; 2010 Jul; 32(2):84-91. PubMed ID: 20693968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB.
    Ma Y; Wang J; Liu L; Zhu H; Chen X; Pan S; Sun X; Jiang H
    Cancer Lett; 2011 Feb; 301(1):75-84. PubMed ID: 21078540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
    J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
    Gao J; Jia WD; Li JS; Wang W; Xu GL; Ma JL; Ge YS; Yu JH; Ren WH; Liu WB; Zhang CH
    J Int Med Res; 2010; 38(4):1413-27. PubMed ID: 20926014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.